natgillin/translations-raw huggingface dataset:
It must not be used in patients who have ever had loss of vision because of a problem called non- arteritic anterior ischaemic optic neuropathy (NAION) that affects the blood flow to the nerve in the eye.
Zdravilo se ne sme uporabljati pri bolnikih, ki so v preteklosti izgubili vid zaradi nearteritične anteriorne ishemične optične nevropatije (NAION), ki vpliva na dotok krvi v očesni živec.
It must not be used in patients who have had arrhythmia (unstable heartbeat) in the past.
Ne sme se uporabljati pri bolnikih, ki so v preteklosti imeli aritmijo (nestabilen srčni utrip).
It must not be used in patients who have had severe heart disease or an auto-immune disease (a disease caused by the body’s own defence system attacking normal tissue), or in children or adolescents who have had severe mental disorders, particularly severe depression, thoughts about committing suicide or suicide attempts.
Ne sme se uporabljati pri bolnikih s hudim srčnim obolenjem ali avtoimunsko boleznijo (boleznijo, ki jo povzroča lastni obrambni sistem telesa, ki napada normalno tkivo) ter otrocih in mladostnikih s hudimi duševnimi boleznimi, zlasti hudo depresijo, samomorilnimi mislimi ali poskusi samomora.
It must not be used in patients who have heart failure, problems with their liver, an ‘acute coronary syndrome’ such as unstable angina (a severe type of chest pain that changes in intensity) or certain types of heart attack, or complications of diabetes (diabetic ketoacidosis or diabetic precoma).
Ne smejo ga uporabljati bolniki s srčnim popuščanjem, težavami z jetri, akutnim koronarnim sindromom, kot je nestabilna angina pektoris (huda vrsta bolečine v prsih, katere jakost se spreminja) ali določene oblike srčnega napada ali bolniki z zapleti sladkorne bolezni (diabetično ketoacidozo ali diabetično predkomo).
It must not be used in patients who have or have had a severe infection within the past two weeks or in patients with a neutrophil count of less than 1,500 per mm3 for the first administration or less than 1,000/mm3 for subsequent administrations or a platelet count less than 100,000 per mm3.
Ne sme se uporabljati pri bolnikih, ki imajo ali so v zadnjih dveh tednih imeli hudo okužbo, ali pri bolnikih s številom nevtrofilcev pod 1 500 na mm3 pri prvem odmerjanju zdravila oziroma manj kot 1 000/mm3 pri nadaljnjih odmerjanjih ali številom trombocitov pod 100 000 na mm3.
It must not be used in patients who have poorly controlled high blood pressure.
Ne sme se uporabljati pri bolnikih, pri katerih visok krvni tlak ni zadovoljivo nadzorovan.
It must not be used in patients who have severe problems with their liver or signs of liver problems in the blood, or who are taking St John’s wort (a herbal preparation used to treat depression).
Ne sme se uporabljati pri bolnikih, ki imajo resne težave z jetri ali znake v krvi, ki kažejo na težave z jetri, ali pri bolnikih, ki jemljejo šentjanževko (pripravek rastlinskega izvora za zdravljenje depresije).
It must not be used in patients with diabetic ketoacidosis or diabetic pre-coma (a dangerous condition that can occur in diabetes), patients with moderately to severely reduced kidney function or with acute (sudden) conditions which can affect kidney function, patients with diseases which can cause tissue hypoxia (where the tissue is deprived of adequate oxygen supply) such as heart failure or difficulty breathing, patients with reduced liver function, alcohol poisoning or alcoholism.
Ne smejo ga uporabljati bolniki z diabetično ketoacidozo ali diabetično predkomo (nevarnim stanjem, ki se lahko pojavi pri sladkorni bolezni), bolniki z zmernimi do hudimi težavami z ledvicami ali z akutnimi (nenadnimi) boleznimi, ki prizadenejo delovanje ledvic, bolniki z boleznimi, ki lahko povzročijo hipoksijo tkiv (kadar tkivo ni zadostno oskrbovano s kisikom), kot je srčno popuščanje ali težave z dihanjem, bolniki z zmanjšanim delovanjem jeter ali alkoholno zastrupitvijo ter alkoholiki.
It must not be used in patients with hypernatraemia (increased sodium levels in the blood) and in pregnant and breastfeeding women.
Ne sme se uporabljati pri bolnikih s hipernatriemijo (zvišanimi ravnmi natrija v krvi) ter pri nosečnicah in ženskah, ki dojijo.
It must not be used in patients with permanent atrial fibrillation of unknown duration or lasting for more than six months when the doctor has decided not to try to restore normal rhythm.
Prav tako ga ne smejo uporabljati bolniki s permanentno atrijsko fibrilacijo, katere trajanje ni znano ali ki traja več kot šest mesecev in pri kateri se zdravnik ni odločil za vzpostavitev normalnega ritma.
It must not be used in patients with severe aortic stenosis (narrowing of the aorta), low systolic blood pressure (blood pressure when the heart is contracting), advanced heart failure (when the heart does not pump enough blood around the body), some types of altered electrical activity in the heart or a very slow heart rate.
Ne sme se uporabljati pri bolnikih s hudo aortno stenozo (zoženjem aorte), nizkim sistoličnim krvnim tlakom (krvnim tlakom, ko se srce skrči), napredovalim srčnim popuščanjem (ko srce ne zmore prečrpati dovolj krvi po telesu), določenimi spremembami električne aktivnosti srca ali zelo počasnim srčnim utripom.
It must not be used in patients with severe kidney disease or hyperchloraemic acidosis (excess acid in the blood caused by too much chloride).
mejo ga uporabljati bolniki s hudim obolenjem ledvic ali hiperkloremično acidozo (preveč kisline v krvi, ki jo povzroča preveč klorida).
It must not be used in patients with severe liver disease or who are taking any of the following medicines:
Ne sme se uporabljati pri bolnikih z resnimi obolenji jeter ali pri osebah, ki jemljejo katero od naslednjih zdravil:
It must not be used in patients with the following conditions: glucose-6-phosphate dehydrogenase deficiency (G6PD),
Zdravila ne smejo uporabljati bolniki z naslednjimi vrstami obolenj: pomanjkanjem glukoza-6-fosfat dehidrogenaze (G6PD),
It must not be used in people who have porphyria (an inability to break down chemicals called porphyrins) or people who have certain skin diseases of different origins caused by exposure to light.
Ne sme se uporabljati pri osebah s porfirijo (nezmožnostjo razgradnje kemičnih snovi, imenovanih porfirini) in osebah z nekaterimi kožnimi boleznimi različnih izvorov, ki jih povzroča izpostavitev svetlobi.
It must not be used in people with a heart problem called ‘congenital long QTc syndrome’ or who have a QTc interval over 480 milliseconds.
Prav tako ga ne smejo uporabljati osebe z motnjo delovanja srca, imenovano prirojeni sindrom podaljšanega intervala QTc, ki znaša več kot 480 milisekund.
It must not be used in premature babies.
Zdravilo se ne sme uporabljati pri nedonošenčkih.
It must not be used in rabbits or in cases of hypersensitivity (allergy) to any of the ingredients.
Ne sme se uporabljati pri kuncih ali v primerih preobčutljivosti (alergije) na katero koli sestavino.
It must not be used in women who are breast-feeding.
Zdravila ne smejo uporabljati ženske, ki dojijo.
It must not be used in women who are pregnant or breast- feeding.
Ne smejo ga uporabljati bolnice, ki so noseče ali dojijo.
It must not be used in women who are pregnant, breast-feeding or by women who could become pregnant and who are not using appropriate contraceptives.
Ne smejo ga uporabljati bolnice, ki so noseče, ki dojijo ali ženske, ki bi lahko zanosile, in tiste, ki ne uporabljajo ustreznih kontracepcijskih sredstev.
It must not be used in women who are pregnant, breast-feeding or by women who could become pregnant and who are not using appropriate contraceptives.
Ne smejo ga uporabljati bolnice, ki so noseče, ki dojijo, ali ženske, ki bi lahko zanosile, in tiste, ki ne uporabljajo ustreznih kontracepcijskih sredstev.
It must not be used in women who are pregnant, breastfeeding or by women who could become pregnant and who are not using appropriate contraceptives.
Ne smejo ga uporabljati nosečnice, doječe matere ali ženske, ki bi lahko zanosile, in ženske, ki ne uporabljajo ustreznih kontracepcijskih sredstev.
It must not be used in women who could become pregnant, unless they take all of the necessary steps to ensure that they are not pregnant before treatment and that they do not become pregnant during or soon after treatment.
Prav tako se ne sme uporabljati pri ženskah, ki bi lahko zanosile, razen če z ustreznimi ukrepi poskrbijo za to, da niso noseče pred zdravljenjem in da ne zanosijo med zdravljenjem ali kmalu po njem.
It must not be used together with St John’s wort (a herbal medicine used to treat depression).
Ne sme se uporabljati skupaj s šentjanževko (zeliščnim pripravkom, namenjenim za zdravljenje depresije).
It must not be used with other medicines that contain fampridine or medicines known as ‘inhibitors of organic cation transporter 2’ such as cimetidine.
Ne sme se uporabljati sočasno z drugimi zdravili, ki vsebujejo fampridin, ali zdravili, znanimi kot „zaviralci organskih kationskih prenašalcev 2“, kot je cimetidin.
It must only be used if the cartridge is intact and the solution is clear, colourless, with no solid particles visible, and if it is of water-like consistency.
Uporabite ga le, če je vložek nepoškodovan in raztopina v njem bistra, brezbarvna, ne vsebuje vidnih trdnih delcev in je vodi podobne konsistence.
It must only be used if the cartridge is intact and the solution is clear, colourless, with no solid particles visible.
Uporabite ga le, če je vložek nepoškodovan in raztopina v njem bistra, brezbarvna, brez vidnih trdnih delcev.
It must only be used if the solution is clear, colourless, with no solid particles visible.
Uporabiti se jo sme le, če je raztopina bistra, brezbarvna in v njej ni vidnih trdnih delcev.
It nch up the tissue and inject Zutectra ng this site.
Na tem mestu boste sami težko stisnili tkivo, dvignili in injicirali zdravilo Zutectra.
It needs to be treated at once.
Potrebujete takojšnjo zdravniško pomoč.
It presumably undergoes hydrolysis within a short time; its metabolites’ pharmacokinetics and pharmacodynamics are not understood yet.
Predvidevajo, da je hitro izpostavljen hidrolizi; farmakokinetika in farmakodinamika njegovih presnovkov pa še ni znana.
It prevents viraemia in sheep and cattle and reduces clinical signs in sheep when infected with bluetongue virus serotype 8.
Preprečuje viremijo pri ovcah in govedu ter zmanjšuje klinične znake pri ovcah, ki so okužene s serotipom 8 virusa bolezni modrikastega jezika.
It provides contrast enhancement and facilitates visualization and helps with characterization of focal lesions and abnormal structures in the CNS and liver in adult patients and in children of two years and older with known or highly suspected pathology.
Omogoča krepitev kontrasta ter izboljša prikaz in pomaga pri karakterizaciji fokalnih lezij in nenormalnih struktur v osrednjem živčevju in jetrih odraslih bolnikov in otrok, starih dve leti ali več, z znano patologijo ali močnim sumom nanjo.
It provides contrast enhancement and facilitates visualization and helps with the characterization of focal lesions and abnormal structures in the CNS and liver in adult patients and in children of two years and older with known or highly suspected pathology.
Omogoča krepitev kontrasta, izboljša prikaz in pomaga pri karakterizaciji fokalnih lezij in nenormalnih struktur v osrednjem živčevju in jetrih odraslih bolnikov in otrok, starih dve leti ali več, z znano patologijo ali močnim sumom nanjo.
It readily crosses the blood brain barrier and has an apparent volume of distribution in the range of 1.8 – 2.7 l/kg.
Rivastigmin hitro prehaja skozi krvno- možgansko pregrado, navidezni volumen porazdelitve pa je v območju 1,8 – 2,7 l/kg.
It readily crosses the blood brain barrier and has an apparent volume of distribution in the range of 1.8-2.7 l/kg.
Dobro prehaja skozi krvnomožgansko pregrado in ima navidezni volumen porazdelitve v območju 1,8–2,7 l/kg.
It readily crosses the blood brain barrier and has an apparent volume of distribution in the range of 1.8–2.7 l/kg.
Dobro prehaja skozi krvnomožgansko pregrado in ima navidezni volumen porazdelitve v območju 1,8-2,7 l/kg.
It readily crosses the blood brain barrier and has an apparent volume of distribution in the range of 1.8–2.7 l/kg.
Dobro prehaja skozi krvnomožgansko pregrado in ima navidezni volumen porazdelitve v območju 1,8–2,7 l/kg.
It recommended that Cystadane be given marketing authorisation.
Priporočil je, da se za zdravilo Cystadane podeli dovoljenje za promet.
It reduces inflammation by reducing the production of immune cells called ‘lymphocytes’, which are responsible for inflammation.
Zdravilo ublaži vnetje z zmanjšanjem tvorjenja imunskih celic, imenovanih limfociti, ki povzročajo vnetje.
It reduces inflammation by reducing the production of immune cells called ‘lymphocytes’, which are responsible for inflammation.
Zdravilo ublaži vnetje z zmanjšanjem tvorjenja imunskih celic, imenovanih „limfociti“, ki povzročajo vnetje.
It reduces inflammation by reducing the production of immune cells called ‘lymphocytes’, which are responsible for inflammation.
Zdravilo zmanjšuje vnetje tako, da zmanjša tvorjenje imunskih celic, imenovanih „limfociti“, ki povzročajo vnetje.
It reduces inflammation by reducing the production of immune cells called ‘lymphocytes’, which are responsible for inflammation.
Zmanjša vnetje tako, da zmanjša nastajanje imunskih celic, imenovanih „limfociti“, ki povzročajo vnetje.
It reduces leukocyte infiltration into the inflamed tissue.
Deluje protivnetno, antieksudativno, analgetično in antipiretično.Zmanjša infiltracijo levkocitov v vneto tkivo.
It replaces the missing factor VIII, thereby helping the blood to clot and giving temporary control of the bleeding disorder.
Simoktokog alfa nadomesti manjkajoči faktor VIII in s tem pomaga pri strjevanju krvi ter omogoči začasen nadzor nad motnjo strjevanja krvi.
It replaces the missing factor X, thereby helping the blood to clot and giving temporary control of bleeding.
Nadomešča manjkajoči faktor X ter tako pripomore k strjevanju krvi in omogoči začasen nadzor nad krvavitvijo.
It represents approximately 10% of the concentration of valdecoxib; because of this metabolite’s low concentration, it is not expected to contribute a significant clinical effect after administration of therapeutic doses of parecoxib.
Predstavlja približno 10 % koncentracije valdekoksiba; zaradi majhne koncentracije tega presnovka ni pričakovati, da bi imel pri uporabi terapevtskih odmerkov parekoksiba pomemben klinični učinek.
It requires further dilution and is for single-use only
Treba jo je še razredčiti in je samo za enkratno uporabo.
It restores normal heart rhythm by blocking channels through which charged particles of potassium and sodium move in and out of the muscle cells in the atria.
Obnovi normalen srčni utrip z blokiranjem kanalov, skozi katere potujejo nabiti delci kalija in natrija v mišične celice preddvora in iz njih.
It selectively inhibits the early synthesis of ergosterol, which is an essential component of the membrane of yeasts and fungi including Malassezia pachydermatis (MIC90 of 2 µg/ml).
Selektivno zavira zgodnjo sintezo ergosterola, ki je glavna komponenta membrane kvasovk in glivic, vključno z glivico Malassezia pachydermatis (MIC90 2 µg/ml).
It shall address the following key elements:
Naslovilo bo naslednje ključne elemente:
It shall be a multi-centre, multinational and prospective observational disease registry of patients diagnosed with severe hepatic VOD following haematopoietic stem cell plantation (HSCT) and enroll patients treated with defibrotide, other treatments or supportive care.
To mora biti multicentrični, multinacionalni in prospektivni opazovalni register bolezni z bolniki z diagnozo hude jetrne VOB po presaditvi krvotvornih matičnih celic (PKMC) ter mora vključevati bolnike, zdravljene z defibrotidom, drugimi oblikami zdravljenja ali podporno nego.
It shares the amino acid sequence with urinary hCG.
Ima enako zaporedje aminokislin kot iz urina pridobljeni hCG.
It should also be noted that female patients may have a higher risk of liver injury (see section 4.8).
Prav tako je treba omeniti, da je lahko tveganje za poškodbo jeter večje pri ženskah (glejte poglavje 4.8).
It should also be taken with meals to reduce the gastrointestinal adverse reactions associated with metformin.
Treba ga je jemati ob obrokih, da se zmanjšajo neželeni učinki metformina na prebavila.
It should also be taken with meals to reduce the gastrointestinal undesirable effects associated with metformin (see section 4.2).
Treba ga je jemati ob obrokih, da se zmanjšajo neželeni učinki metformina na prebavila. (glejte poglavje 4.2).
It should also not be used in patients who have had cancer, who have active tuberculosis or another severe infection, who have other types of psoriasis, or who have low levels of immunity.
Prav tako ga ne smejo uporabljati bolniki, ki so imeli raka, ki imajo aktivno tuberkulozo ali druge hude okužbe, druge oblike psoriaze ali oslabljen imunski sistem.
It should also not be used in patients who have kidney disease or who are taking other medicines that might be harmful to the kidneys, or in patients who cannot take probenecid or other ‘sulfa-containing’ medicines.
Zdravila prav tako ne smejo uporabljati bolniki z ledvičnimi obolenji, bolniki, ki jemljejo druga zdravila, ki lahko škodujejo ledvicam, ali bolniki, ki ne morejo jemati probenecida ali drugih zdravil, ki vsebujejo žveplo.
It should also not be used in patients with alcohol intoxication (excessive alcohol consumption) or alcoholism, or during breast- feeding.
Prav tako se ne sme uporabljati pri bolnikih z akutno zastrupitvijo z alkoholom (prekomerno uživanje alkohola) ali v primeru alkoholizma oziroma med dojenjem.
It should also not be used in patients with type 1 (insulin-dependent) diabetes who do not have any ‘C-peptide’ in their blood (a marker of type 1 diabetes).
Prav tako ga ne smejo uporabljati bolniki s sladkorno boleznijo tipa 1 (od insulina odvisno sladkorno bolezen), ki nimajo nobenega C-peptida v krvi (označevalca sladkorne bolezni tipa 1).
It should also not be used in people who have:
Prav tako ga ne smejo uporabljati osebe, ki imajo:
It should also not be used in pregnant cows or heifers which are intended to produce milk for human consumption within 2 months of calving.
Zdravilo se ne daje brejim kravam ali telicam, katerih mleko je namenjeno prehrani ljudi, v obdobju dveh mesecev pred pričakovano telitvijo.
It should always be taken in combination with other prescribed antiepileptic medicines under the direction of a doctor.
To zdravilo mora otrok vedno jemati v kombinaciji z drugimi predpisanimi zdravili proti epilepsiji po navodilih zdravnika.
It should appear punctured and empty.
Videti morate, da je predrta in prazna.
It should be administered directly into the child's mouth using the graduated oral syringe, calibrated in mg of propranolol base, supplied with the oral solution bottle (see instructions for use in section 3 of the patient information leaflet).
Dajati ga je treba neposredno v otrokova usta z uporabo graduirane brizge za peroralno dajanje, umerjene v miligramih propranolola, ki je priložena steklenici s peroralno raztopino (glejte navodila za uporabo v poglavju 3 navodil za uporabo).
It should be administered into the centre of the deltoid muscle.
Zdravilo se injicira v sredino deltoidne mišice.
It should be administered under medical supervision with consideration of the potential for increased incidence of central nervous system adverse reactions (see section 4.8).
Odmerek se mora dati pod zdravniškim nadzorom, pri čemer je treba upoštevati možnost povečanja incidence neželenih učinkov na centralni živčni sistem (glejte poglavje 4.8).
It should be assessed prior to starting treatment with stiripentol.
Pred zdravljenjem s stiripentolom je potrebno pregledati jetrno funkcijo.
It should be clear and colourless with no particles.
Biti mora bistra in brezbarvna, brez delcev.
It should be clear or slightly opalescent, colourless or pale yellow, and may contain small white or almost transparent particles of protein.
Raztopina mora biti bistra ali rahlo svetlikajoča, brezbarvna ali bledorumena in lahko vsebuje majhne bele ali skoraj prozorne delce beljakovine.
It should be clear or slightly opalescent, colourless or pale yellow, and may contain small white or almost transparent particles of protein.
Raztopina mora biti bistra do rahlo opalescentna, brezbarvna ali bledorumena ter lahko vsebuje majhne bele ali skoraj prosojne delce beljakovine.
It should be clear to pale yellow.
Tekočina mora biti bistra do bledo rumena.
It should be considered that amiodarone may have a long duration of action after discontinuation due to its long half life.
Upoštevati je treba, da lahko amiodaron zaradi svojega dolgega razpolovnega časa deluje še zelo dolgo po prenehanju uporabe.
It should be diluted in 50 ml of sterile 0.9% sodium chloride solution before intravenous administration to the patients.
Pred intravensko administracijo bolnikom ga moramo razredčiti v 50 ml sterilne raztopine 0,9-% natrijevega klorida.
It should be dissolved fully in water, juice, milk, formula or food immediately before being taken.
Prašek je treba neposredno pred zaužitjem popolnoma raztopiti v vodi, soku, mleku ali hrani.
It should be emphasised that stress echocardiography, which can mimic an ischaemic episode, could potentially increase the risk of SonoVue utilisation.
Potrebno je poudariti, da lahko ehokardiografski stres, ki lahko oponaša ishemično epizodo, potencialno poveča tveganje uporabe zdravila SonoVue.
It should be ensured that the vaccine suspension is mixed regularly in a gentle way during the vaccination session to guarantee that the vaccine suspension remains homogenous and that the correct vaccine virus titer is administered (e.g. when automatic in- ovo injection machines are used or during long vaccination sessions).
Zagotovite redno, nežno mešanje suspenzije cepiva med postopkom cepljenja, da zagotovite homogenost suspenzije cepiva in, da se odmeri pravilen virusni titer cepiva (npr. ob uporabi avtomatskih in-ovo injekcijskih naprav ali med dolgimi postopki cepljenja).
It should be explained to patients that Oncaspar should not be used at the same time as other medicines associated with an increased risk of bleeding (see “Other medicines and Oncaspar”).
Bolnikom moramo pojasniti, da se zdravilo Oncaspar ne sme uporabljati sočasno z drugimi zdravili, povezanimi s povečanim tveganjem za krvavitev (glejte poglavje „Druga zdravila in zdravilo Oncaspar“).
It should be given in an officially declared pandemic and according to official guidance.
Dati se sme v primeru uradno razglašene pandemije in v skladu z uradnimi smernicami.
It should be given where resuscitation equipment is available in case of severe allergic reaction (anaphylaxis).
Dajati se mora v okolju, kjer je na voljo oprema za oživljanje v primeru resnih alergijskih reakcij (anafilaksije).
It should be handled with care.
Z njim je treba ravnati pazljivo.
It should be injected slowly, deep into the muscle.
Treba ga je injicirati počasi, globoko v mišico.
It should be inspected visually for particulate matter and discoloration before administration.
Pred dajanjem je treba vizualno preveriti prisotnost delcev in razbarvanja.
It should be inspected visually for particulate matter and discolouration prior to administration.
Pred uporabo je treba optično preveriti, da raztopina ne vsebuje trdnih delcev in da njena barva ni spremenjena.
It should be kept in
Zavedati se je treba, da z uporabo
It should be kept in mind that the half-life of protein C may be severely shortened in certain clinical conditions such as acute thrombosis with purpura fulminans and skin necrosis.
Ne pozabite, da je razpolovna doba proteina C lahko močno skrajšana pri določenih kliničnih stanjih, npr. pri akutni trombozi s purpuro fulminans in kožno nekrozo.
It should be left for 4 hours, and then be removed.
Na rani se pusti 4 ure, nato pa se odstrani.
It should be noted however that pregnancy itself as well as OHSS also carry an increased risk of thrombo-embolic events.
Vendar pa moramo upoštevati, da nosečnost sama kot tudi OHSS prinašata povečano tveganje za trombembolične dogodke.